⌘K
t
On 5 September 2022, Destiny Pharma plc announced the expiry of 602,000 options over ordinary shares under the Company's EMI Scheme 2000. Of these, 406,500 options related to Dr William Love, Chief Scientific Officer. Following this expiry, 8,875,230 options remain outstanding in the Company, with Dr Love holding options over 916,236 ordinary shares, representing 1.25% of the Company's ordinary shares.
| Date | 5 Sept 2022 |
| Time | 14:15:36 |
| Category | Director/PDMR dealings |
| ID | 3089Y |
Destiny Pharma plc
("Destiny Pharma" or the "Company")
Expiry of share options
Brighton, United Kingdom - 5 September 2022 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life threatening infections, announces that 602,000 options ("Options") over ordinary shares of 1 pence in the Company have expired under the Company's EMI Scheme 2000, of which 406,500 Options relate to Dr William Love, Chief Scientific Officer.
Following the expiry of the Options, a total of 8,875,230 options remain outstanding in the Company with Dr Love holding options over 916,236 ordinary shares representing 1.25% of ordinary shares in the Company.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 127 370 4440
Optimum Strategic Communications
Mary Clark / Manel Mateus / Eleanor Cooper
+44 (0) 203 922 0891
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500
MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12
Stern IR
Lilian Stern / Janhavi Mohite
+1-212-362-1200
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV™, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.
For further information on the company, please visit www.destinypharma.com